LEGEND BIOTECH CORP

Legend Biotech’s fall from a $37.50 high to $19.88, a negative P/E of -41.05, raises red flags on its cell‑therapy promise and investor confidence.

Legend Biotech’s cell‑therapy venture faces steep financial hurdles, with a negative P/E and volatile stock price, raising concerns for investors and industry analysts.